You are here

  • Home
  • Archive
  • Volume 10, Issue 2
  • Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial

Citation Tools

Article menu

Download PDFPDF

XML
Health economics
Original research
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Wang H, Huang L, Gao P, et al
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
BMJ Open 2020;10:e030738. doi: 10.1136/bmjopen-2019-030738